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Abstract 
Duchenne muscular dystrophy (DMD) is a severe and lethal early childhood 
muscle disorder. It is due to genetic mutations in the DMD gene that disrupt dystrophin 
protein expression in all striated muscles. As a result of loss of dystrophin, skeletal 
muscles undergo cycles of degeneration and chronic inflammation. Skeletal muscle 
normally has the ability to regenerate and repair itself. However, in DMD, muscle 
regeneration progressively fails leading to a loss of muscle mass and hence, muscle 
function. The mechanisms involved in this progressive failure of muscle regeneration are 
not fully understood. However, they appear tightly linked to a parallel progressive 
increase in fibrotic tissue that gradually replaces functional muscle tissue. Understanding 
the molecular mechanisms that lead to the progressive loss of muscle function is essential 
because it can reveal new treatment opportunities to halt disease progression and prolong 
lifespan in these patients. 
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Towards this goal, our laboratory has been studying the effects of the muscle 
environment on the fate choices of interstitial muscle stem cells. These stem cells have 
the unique ability to differentiate into muscle thus contributing to regeneration, or into 
fibrotic cells, thus potentially shifting the balance toward fibrosis. We have previously 
shown that the dystrophic muscle environment blocks the myogenic differentiation of 
interstitial stem cells and instead promotes their differentiation into fibrotic lineages 
(Penton et al., PLoS ONE, 2013). We discovered that myogenic differentiation of 
interstitial stem cells is dependent upon active Hedgehog signalling and that the 
dystrophic muscle environment inhibits Hedgehog signalling in these stem cells. Because 
Hedgehog signalling has not been studied in muscle disease, this thesis focuses on 
defining the broader role of this signalling pathway in disease progression in DMD, using 
the well-established mdx mouse model of DMD. We treated dystrophic mdx mice in vivo 
with a specific Hedgehog activator in order to restore Hedgehog signalling in dystrophic 
muscles to wild type levels. Short term treatment (1 week) significantly improved muscle 
regeneration. Interestingly, we found that inflammation was decreased along-side the 
regenerative effects. Long-term treatment (2 months) of mdx mice with the Hedgehog 
agonist lead to a decrease in fibrosis and a significant improvement in motor function.   
 We show for the first time that Hedgehog signalling is impaired in muscular dystrophy 
and that this contributes to disease progression. Our results also indicate that sustained 
pharmacological activation of Hedgehog signalling to wild type levels has positive 
effects on regeneration, inflammation, fibrosis and motor function. Further research is 
needed to better understand the cellular and molecular mechanisms involved in 
Hedgehog signalling and to identify Hedgehog inhibitors present in dystrophic muscle. 
This may reveal new potential targets for therapeutic intervention in muscular dystrophy. 
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Introduction 
Duchenne muscular dystrophy (DMD) is a lethal muscle disease that affects about 
1 in every 4,087 live births (Mendell et al., 2012b). DMD is characterized by progressive 
muscle weakness and degeneration due to mutations in the DMD gene which produces 
the intracellular protein, dystrophin. This protein plays a critical role in signaling and 
structure within muscle (Lapidos et al., 2004). When the expression or function of 
dystrophin is impaired, the muscle fiber becomes more permeable which can lead to fiber 
necrosis. While increased damage is the primary outcome of loss of dystrophin, many 
secondary issues also contribute to muscle pathology (Williams and Bloch, 1999). When 
muscle is damaged, it has the amazing capacity to repair and regenerate itself.  Three 
main components of muscle repair are altered in DMD which include a chronic presence 
of inflammation, the deposition of fibrotic tissue and impaired regeneration. These 
aspects are an important area of study in better understanding DMD.  
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Patients with DMD  
DMD is an X chromosome linked disease that mainly affects boys. The disease is 
usually not diagnosed until between two and five years of age. At a young age, changes 
in motor function are signaled by indicators such as difficulty in standing up from the 
ground or walking up stairs. While these deficits are noticed, DMD patients tend to reach 
most milestones in motor function until seven years of age (Wicklund, 2013). However, 
without intervention patients usually loose ambulation by age 12. In addition to loss of 
ambulation patients also have respiratory insufficiency and cardiac disease. Aside from 
these debilitating symptoms, patients with DMD are more likely to have cognitive 
impairment involving language, attention deficit hyperactivity disorder, autism spectrum 
disorder, or obsessive compulsive disorder (Hendriksen and Vles, 2008).  Without 
intervention, death occurs around age 20 due to cardiac or respiratory disease. However, 
current intervention and research have helped extend the average life-span to 25 years 
with some patients living into their 30’s (Wicklund, 2013). 
Current Research  
Since the primary cause of DMD is the loss of the dystrophin protein, researchers 
are working to restore dystrophin function. Due to the size of the gene, 2.4Mb, repairing 
functionality is difficult. One approach to restore functionality includes exon skipping 
targeted at the pre-mRNA level. This approach allows the reading frame to be restored in 
case of deletion mutations, or leads to the removal of mutated exons containing 
premature stop codons that are very common in DMD (Mendell et al., 2012a). Exon 
skipping is a large area of focus as it has the potential to be applied to 83% of DMD 
patients. However, using exon skipping is difficult as different sequences for skipping 
would be required for individual patients (Fairclough et al., 2011). Another treatment 
approach is gene therapy, which uses clinically safe viral vectors to deliver a functional 
copy of dystrophin. Because the DMD gene is the largest in the human genome, a full 
replacement is not feasible. Therefore, gene therapy introduces smaller or micro versions 
of dystrophin that function the same as, or close to the whole gene. These approaches are 
important in targeting the disease but they require an adequate amount of muscle in the 
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patient to have a beneficial effect. DMD has many secondary characteristics that worsen 
the disease over time which can alter the effectiveness of these approaches. Since these 
characteristics such as inflammation, regeneration and fibrosis are important in 
maintaining muscle, they are also a target of current research. Improving the secondary 
effects of the disease can contribute to the improvement of the efficacy of the treatments 
mentioned above. Currently, treatments in human DMD patients target inflammation 
using glucocorticoid corticosteroids. While it does lengthen the time that a patient can be 
ambulatory this intervention does not significantly lengthen life span (Flanigan, 2014). 
Targeting both the functionality of dystrophin and the secondary characteristics of the 
disease are important in studying DMD and new or alternative approaches are an 
important focus in research. 
Muscle Damage  
Inflammatory Response in Muscle Injury  
Dystrophin is essential to cell signaling and cell structure within skeletal muscle. 
Dystrophin is a part of the dystrophin glycoprotein complex (DGC) which helps to link 
the intracellular cytoskeleton to the extracellular matrix (ECM). When dystrophin is not 
produced in DMD patients, the DGC becomes functionally impaired. Because of this 
change in structure, the permeability of the sarcolemma, the cell membrane of a muscle 
fiber, is increased (Shin et al., 2013). Calcium is able to leak through the sarcolemma 
with greater ease which activates proteases and leads to a necrotic fiber (Zhou and Lu, 
2010). As a result of these changes, DMD patients experience chronic muscle damage. 
When a muscle fiber is damaged the first step of repair involves the recruitment of 
inflammatory cells to the damage site. The response is present in order to aid in cleaning 
away any unneeded or unwanted material as well as to help stabilize functions of the 
repair process. These cells are mainly myeloid cells. Within 2 hours of muscle damage, 
neutrophils appear in the damaged area. In order to clean out the damaged tissue, 
macrophages that are phagocytic are recruited to the damaged area. These are also known 
as M1 macrophages that are pro-inflammatory and express inducible nitric oxide 
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synthase (iNOS) to produce cytotoxic levels of nitric oxide. The primary function of M1 
macrophages is to help clear debris in the damaged area. M1 macrophages are then 
switched to the M2 phenotype which is non-phagocytic. While the timing and cause of 
the switch in phenotype is not completely understood, it is thought that phagocytosis of 
debris can cause a switch in phenotype (Fadok et al., 1998). When M2 macrophages are 
activated, they can release anti-inflammatory cytokines that help to deactivate M1 
macrophages (Tidball et al., 2014). M2 macrophages promote tissue repair and their 
activity is in part controlled by CD206, a mannose receptor. The activation and 
expression of these inflammatory cells is highly regulated in healthy muscle repair, but 
the process in DMD is perturbed because of the chronic nature of muscle damage. In 
dystrophic muscle there is a coexistence of areas of active degeneration and areas of 
regeneration within the same muscle. Therefore, in DMD there is a chronic presence of 
these inflammatory cells and a temporal overlap of signals that regulate the 
differentiation and activation of M1 and M2 macrophages. The persistent presence of 
inflammatory cells can turn the beneficial signaling into one that promotes muscle 
damage (Abdel-Salam et al., 2009), impairs regeneration (Villalta et al., 2009), and 
promotes fibrosis (Zhou et al., 2006). 
 Regeneration  
In order to generate new fibers, muscle stem cells, also known as satellite cells 
become activated. Satellite cells are mononuclear cells located under the basal lamina, a 
layer of the ECM, that surrounds myofibers (Pallafacchina et al., 2013).  Once activated, 
satellite cells proliferate and can either self-renew or differentiate. When satellite cells go 
through this process it is regulated by different basic helix-loop-helix transcription 
factors, which include myogenic factor 5 (Myf5), myoblast determination protein 
(MyoD), myogenin, and muscle regulatory factor (MRF4) which are typically expressed 
in that order (Karalaki et al., 2009). These transcription factors are regulated by the 
transcription factors paired box 7 and 3 (Pax7 and Pax3). Both Pax3 and Pax7 bind to 
promoters of MyoD and Myf5 and regulate their expression in the muscle (Wang and 
Rudnicki, 2012). Pax3 is mainly expressed during embryonic muscle development so 
   
7 
 
most of the focus in DMD has been on Pax7. Pax7 helps regulate the fate of satellite cells 
during proliferation and is down regulated during differentiation (Wang and Rudnicki, 
2012). During satellite cell proliferation, macrophages are present in the damaged area. 
The inflammatory response is meant to be beneficial in repairing the muscle, but in DMD 
the response can sometimes be damaging. This is in part because different macrophages 
are a source of cytokines that can affect satellite cells (Hirata et al., 2003); for example, 
they can delay their myogenic differentiation (Merly et al., 1999).  This is supported by in 
vitro experiments where the presence of M1 macrophages increases satellite cell 
proliferation while decreasing their myogenic differentiation. By contrast, M2 
macrophages increase satellite cell differentiation (Arnold et al., 2007). This suggests that 
alterations in the inflammatory response and presence or absence of different 
macrophages can affect muscle regeneration. When proper satellite cell differentiation 
does not occur, myofiber regeneration is impaired which can give rise to the formation of 
split or branched fibers.  
Branched Fibers  
The fusion of mononuclear satellite cells with each other or with myofibers is what helps 
to form new multinucleated myofibers or regenerate damaged segments of pre-existing 
fibers. When a muscle fiber or a segment of a muscle fiber degenerates, the basal lamina 
is left behind and is used as a scaffold (Turner and Badylak, 2012). Satellite cells 
proliferate, enter this tube of basal lamina, and begin to fuse with each other. The cells 
create multiple small-diameter immature myotubes spanning the length of the 
degenerated myofiber segment. In a normal regenerative process, these myotubes 
increase in diameter as satellite cells continue to differentiate and fuse with them, thus, 
increasing their size. Once the myotubes touch each other and have filled the space 
originally occupied by the myofiber, they fuse with each other and, thus, reconstitute a 
single continuous myofiber. However, in DMD, satellite cell differentiation is impaired 
and myotubes can fail to fuse into one large myofiber within the matrix scaffold. When 
this fusion fails to occur, the individual myotubes stop growing and begin to lay down 
their own individual basal lamina. This allows them to be mechanically more stable and 
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to complete maturation. However, this blocks myotube fusion leading to the formation of 
fibers that are branched (Ciciliot and Schiaffino, 2010). The fibers can branch into two, 
or more individual fibers depending on when the myotubes stop growing and fusing with 
each other (Figure 1).  
Figure 1. Drawing of a branched fiber and 
splitting points in serial sections. Cross 
sections A, B and C show the structure of the 
single fiber at the branching points.  
 
 
Branched fibers are weaker at branching points and consequently, do not function 
as effectively as one continuous fiber. In contrast to non-branched fibers, branched fibers 
have been shown to have reduced isometric force, have altered contraction times (Chan 
and Head, 2011), and be more prone to contraction-induced damage (Chan et al., 2007). 
When there is an increased chance for damage, the fibers are more susceptible to necrosis 
which contributes to the chronic cycle of degeneration and regeneration.  
Fibrosis  
An important part of muscle structure is the extracellular matrix (ECM) which 
helps to provide a scaffold for the muscle. Existing within skeletal muscle are fibroblasts, 
cells that synthesize ECM surrounding muscle. Fibroblasts play an important role during 
regeneration by stimulating the secretion of necessary ECM precursors, including 
proteins such as collagen, to promote structural scaffolding. The production of substances 
needed in the ECM, such as collagens, is tightly regulated in muscle repair (Murphy et 
al., 2011). However, as occurs in DMD patients, the impairment of this process can lead 
to excessive deposition of fibrous tissue which can then damage the structure and 
function of muscle. Different growth factors which are altered in the dystrophic 
environment can promote deposition of fibrotic material such as collagen I. Dystrophic 
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muscle has a different micro environment compared to healthy muscle. This environment 
can cause macrophages to promote fibrosis and is thought to promote the conversion of 
satellite cells to a fibrogenic lineage (Brack and Rando, 2007). A main growth factor that 
is altered in the dystrophic environment is transforming growth factor beta (TGF-β). This 
protein can be secreted from cells such as macrophages and alters the regeneration 
process in muscle. TGF-β can increase fibroblast proliferation and cause increased 
production of collagen (Smith et al., 2007). All of these alterations in DMD promote 
fibrosis in the muscle and reduce the functional capacity of the muscle. Researchers are 
working to target not only fibrosis, but many of the aspects mentioned above in an effort 
to improve the structure and function of dystrophic muscle.   
As a result of the altered and out of sync regeneration and degeneration in DMD, 
research is focused on obtaining a better understanding of the secondary processes 
involved in order to target these processes in the disease. Finding alternative pathways 
which affect the disease is very crucial to understand the disease as a whole and provide 
alternative approaches to treatments and research. One such pathway which is not fully 
understood in terms of its function and purpose in adult muscle is the Hedgehog pathway.  
The Hedgehog Pathway  
Our laboratory has been studying how the muscle environment affects the 
differentiation of interstitial muscle stem cells towards either a myogenic or fibrotic state. 
Interstitial stem cells are distinct from satellite cells and primarily reside in the 
connective tissue in-between myofibers. Members of our lab have previously shown that 
myogenic differentiation of interstitial stem cells is completely blocked in the dystrophic 
environment where these cells appear to instead differentiate into fibroblasts (Penton et 
al., 2013). With the goal of targeting pathways that alter the fate of these stem cells, our 
lab used RT-PCR to identify signaling pathways that are altered in interstitial stem cells 
isolated from muscles of dystrophic mdx mice compared to wild type mice.  We found 
that Hedgehog (Hh) signaling was inhibited in interstitial stem cells from dystrophic 
muscle. Because Hh signaling is important for myogenic fate determination during 
embryonic development, we hypothesized that Hh may similarly regulate the myogenic 
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differentiation of interstitial stem cells in adult muscle. When purmorphamine, an Hh 
agonist, was administered to interstitial stem cells isolated from dystrophic muscle, 
myogenesis was restored. This led us to further investigate what effects Hh signaling 
would have throughout dystrophic muscle. This was particularly important given a recent 
report that decreased Hh signaling in injured wild type muscle impairs regeneration and 
promotes fibrosis(Straface et al., 2009), an outcome similar to dystrophic muscle. The 
mechanisms and significance of the pathway are not well understood, which is why it is 
imperative to study its effects on muscle regeneration.  
History  
Hedghog  was first discovered in drosophila melanogaster in 1980 by Christiane 
Nüsslein-Volhard and Eric Wieschaus(Nusslein-Volhard and Wieschaus, 1980). It was 
named Hh because the mutations caused a spike like appearance on the drosophila larvae 
which look similar to the spikes of a hedgehog. The pathway’s activation is controlled by 
different ligands. Overtime, three ligands in mammals have been discovered: Sonic Hh, 
Indian Hh and Desert Hh. These ligands and the signaling pathway mainly contribute to 
embryonic development but altered activation in adults has been linked to different 
diseases such as cancer(Beachy et al., 2004) or fibrosis(Piccioni et al., 2014).  
Embryonic Developmental Significance  
The Hedgehog (Hh) pathway plays a crucial role in embryonic development. Each 
of the different ligands performs separate roles in embryogenesis. Sonic Hh is important 
in the polarization of the limb bud and notochord. Indian Hh is important in bone and 
cartilage development and Desert Hh is important in germ cell formation (Briscoe and 
Therond, 2013). If Hh is impaired during embryogenesis different developmental 
diseases can occur. Aside from the embryonic importance, Hh has been a focal point of 
research especially in relation to adult function such as in cancers (Ruch and Kim, 2013) 
and more recently, in muscle and its effects on fibrosis (Straface et al., 2009).  
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Pathway Mechanism  
The three Hh ligands bind to a transmembrane protein receptor known as patched-1 
(Ptch). Ptch is an inhibitor of the transmembrane protein smoothened (Smo). Upon ligand 
binding, Ptch is unable to inhibit Smo. Once Smo is activated, it can activate Gli2 and 
Gli3, two transcription factors, which then promote the transcription of Hh target genes 
including but not limited to Gli1, Hhip, and Ptch. Since Ptch is a product of the pathway 
it participates in a negative feedback cycle. A known Hh agonist, purmorphamine can 
activate the Hh pathway by directly binding and activating Smo. Therefore, 
purmorphamine bypasses the inhibition by Ptch and the need for Hh ligands. We used 
purmorphamine as a specific Hh agonist to study the effects of Hh activation in 
dystrophic mdx mice (Figure 2).  
 
Figure 2 A. In the absence of ligands, Ptch blocks the activation of Smo and hence, the activation 
of the Hh pathway. B. When a Hh ligand binds to Ptch this stops the inhibition that Ptch has on 
Smo. When Smo is no longer blocked the pathway can become active. When active, the pathway 
transcribes different target genes via activation of the transcription factors Gli2 and Gli3. C. We 
have bypassed the need for Hh ligands and use the Hh agonist purmorphamine, to directly bind to 
and activate Smo and the pathway.   
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Significance in post natal muscle 
While the Hh pathway plays an important role in embryonic development, its activation 
and inhibition post natally is also important in the body. When the activity of the 
signaling pathway is unregulated in muscle, its activation or repression can have 
deleterious effects. The signaling of the pathway is noted to be located at the primary 
cilia of myogenic cells and that active Hh signaling promotes myogenic differentiation 
(Fu et al., 2014). Inhibition of Hh signaling has also been shown to decrease MyoD and 
Myf5 expression which alters satellite cell activation (Straface et al., 2009; Voronova et 
al., 2013). The regulation of the Hh pathway is not only important in dystrophic muscle 
as studied in my thesis but it is also important in regulating myogenesis and preventing 
fibrosis in healthy skeletal muscle (Straface et al., 2009).   
The mdx Mouse 
While completing the study of DMD for this thesis, I have utilized the mdx 
mouse. This model was first reported in 1984 after a spontaneous mutation in C57BL/10 
mice arose (Bulfield et al., 1984). The mutation is present in the DMD gene on the X 
chromosome in the mouse as it is in the human. While the phenotype in the mdx mouse is 
not as severe as in DMD patients, it can give a good indication of potential targets and 
therapies in research. The mice are different from patients with DMD in that while they 
show histopathology similar to humans, they remain ambulant throughout their life span. 
The general progression of the disease is also different than in humans. While in human 
patients there is a continual cycle of degeneration and damage in the muscle the mice 
have what can be referred to as a crisis period. During the first few weeks of life there is a 
continual cycle of degeneration and regeneration in parallel with inflammation. After this 
period the muscle begins to stabilize. Increased fibrosis is detectable by 12 weeks of age 
and remains relatively stable until about 9 months of age when it steadily increases 
concomitant with a decrease in myofiber regeneration. A layout of the disease 
progression in mice by their age can be seen in Figure 3. One known exception to the 
disease progression in mdx mice is the diaphragm. This muscle continues to have cycles 
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of degeneration and regeneration and does not stabilize as other skeletal muscles do. This 
makes the diaphragm a model that is more similar to the pathology seen in humans.  
  
 
 
 
 
 
Figure 3. In limb muscle, starting around 3 weeks of age and peaking around 4 weeks, there is 
chronic inflammation that runs in parallel with the degeneration and regeneration. Once the 
‘crisis’ period ends between 9 and 12 weeks of age the disease stabilizes with detectable levels of 
increased fibrosis which remain constant until about 9 months. After 9 months, fibrosis increases 
continuously and muscle degeneration and inflammation also increase continuously.  
Focus of this thesis 
While there has been a lot of research in understanding DMD, there is much that 
is still unknown. It is important to understand the mechanisms and pathways involved in 
the secondary aspects of the disease. Our lab was working to answer a larger question of 
the effects of Hh inhibition in mdx mice and the long-term effects on fibrosis deposition. 
To answer this question, members of the lab looked at fibrosis deposition after activating 
Hh signaling in mdx mice with purmorphamine for two months. They found that inducing 
Hh signaling significantly decreased the amount of fibrosis in the diaphragm of mdx mice 
along with other pathological characteristics. My research project involved the 
characterization of mdx mice treated with Purmorphamine before the onset of detectable 
fibrosis, in order to gain a better understanding of how Hh signaling modifies fibrosis in 
mdx mice. This thesis not only focuses on the effects of Hh signaling during a chronic 
period of degeneration and regeneration, but also reports on interesting differences in the 
Chronic Inflammation  
Cycles of Degeneration and Regeneration  
Fibrosis  
4 weeks 
of age  
9 8 12 
   
14 
 
response of limb (quadriceps) and diaphragm muscles to Hh activation. While both 
muscle types are frequently studied, the diaphragm is noted as a closer representation of 
human DMD as it is more severely affected by the disease than the limb muscle (Dupont-
Versteegden and McCarter, 1992; Stedman et al., 1991). Having an effect on the 
diaphragm may give a better indication of the impact of Hh signaling in human 
dystrophic muscle.  
The initial cause of DMD is the loss of dystrophin which damages the integrity of 
the muscle fiber. Currently, scientists are aiming to restore, or partially restore dystrophin 
as a therapy for the disease. Research has also shown that many of the outcomes of the 
disease are caused by secondary responses in the muscle environment. Understanding 
these processes may help scientists find alternate treatments in order to lessen the 
characteristics of the disease. The objective of this study is not to try and restore 
dystrophin but rather to study different features that may alter the disease.  The effects of 
Hh signaling will open up different approaches to research and provide insight into 
potential treatment targets.  
Methods 
Mice: Dystrophic mice involved in this experiment are mdx5cv mice originally obtained 
from Jackson Laboratories (B6Ros.Cg-Dmdmdx-5Cv/J) and bred in-house. Wild-type (WT) 
mice also originated from Jackson Laboratories (C57BL/6J) and have been bred in-house. 
Combinations of male and female mice were used for the experiment and are not 
distinguished in separate categories. Mice were kept in similar environments throughout 
the experiment and fed a low fat diet. All procedures involved in this study followed 
protocols approved by the Institutional Animal Care and Use Committee at Nationwide 
Children’s Hospital.  
Purmorphamine injections: Mdx5cv mice were injected intraperitoneally (IP) with 
purmorphamine, an Hh agonist (100ul/10mg) or vehicle solution every 12 hours using 
1mL sub Q 26 5/8 syringes from BD Biosciences.  Purmorphamine was diluted in a 
vehicle solution composed of 10% DMSO, 18% Chremophore and 25% glucose in 
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distilled water. Using this protocol of purmorphamine injections we are able to restore the 
Hh activity back up to WT levels in mdx mice.  
Histology: Dissected diaphragm and quadriceps muscle were mounted in trigacanth gum 
and frozen in liquid nitrogen. Tissues were cryosectioned at 10µm.  
Hematoxylin and Eosin: Tissues were stained with Gills-3 Hematoxylin and Eosin-Y. 
Tissues were stained in Hematoxylin for 6 minutes then rinsed in warm water followed 
by a rinse in a 2% Ammonium Hydroxide in water solution followed by a rinse in water. 
Tissues were then dehydrated through a series of ethanol rinses; 30%, 95%, and 100% 
then placed in Xylene and mounted.  
Immunohistochemistry: Tissue sections were fixed according to the primary antibody 
being used. For staining for embryonic myosin heavy chain (eMHC) and Pax7, sections 
were fixed in 4% paraformaldehyde in PBS for 15 minutes. For staining for CD45, 
sections were fixed in acetone at -20 degrees Celsius for 2 minutes then allowed to dry 
completely. All fixed tissues were then washed multiple times in PBS and blocked for 1 
hour at room temperature in 1xPBS, 5% Horse serum and 2% BSA. Next, tissues were 
incubated overnight in the primary antibody solution at 4°C. Following primary 
incubation, sections were incubated for 1 hour at room temperature with the secondary 
antibody in block. Finally, the tissues were stained with DAPI and mounted with NPG 
mounting medium. 
For Pax7 staining, an antigen retrieval step in 10mM Sodium Citrate Solution for 30 
minutes at 100 degrees Celsius was done after fixation in 4% paraformaldehyde.  
For primary antibodies made in mouse (see table), an additional Fab Fragment incubation 
step was included after the 1 hour blocking step above. Fab Fragment at 0.1mg/mL was 
added to the tissues for 2 hours at room temperature. The tissues then went through a post 
fixation in 0.1% paraformaldehyde for 5 minutes before incubation with the primary.   
Antibody  Species  Dilution  Reference  
eMHC Mouse 1:10 DSHB F1.652 
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Pax7 Mouse  1:100 *See below 
CD45 Rat 1:200 BD Biosciences 14-
0451-81 
Laminin Rat 1:400 Sigma L-9393 
Alexa 488 Donkey 
anti-Rat  
Donkey  1:200 Jackson 712-585-
150 
Rhodamine Red 
Donkey anti-Rat 
Donkey  1:200 Jackson 712-295-
150 
Alexa 488 Donkey 
anti-Mouse 
Donkey  1:200 Jackson 712-545-
153 
Fab Fragment 
Donkey anti-Mouse 
IgG 
Donkey 0.1mg/mL Jackson 715-007-
003 
*Pax7 kindly provided by Denis Guttridge, Ohio State College of Medicine, Columbus, 
OH 
Statistical Analysis 
Photographs were taken at 20x magnification. All analyses were done on montages of the 
entire section of muscle created using Slidebook software. Images were taken at the same 
exposure. Staining for eMHC, and Pax7 were quantified using visual representation of 
fibers and all parameters quantified were normalized to the total number of fibers in the 
tissue section. Staining for CD45 was done comparing the total area of the tissue to the 
total area of CD45 positive stained sections. When area was determined all images were 
adjusted to the same threshold value in ImageJ (NIH). Threshold values were adjusted for 
a few sections where the staining was visually uniformly dimmer. All analyses of tissues 
were done using ImageJ (NIH). 
All image analysis between control mice and treated mice was done using a two-tailed 
unpaired Student’s t-test. Significance was set at P<0.05.  
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Rational For My Study  
Our lab began looking at Hh signalling when we found that it restored myogenesis in 
interstitial satellite cells. Since these cells took on a myogenic rather than fibrotic fate we 
hypothesized that restoring Hh activation in muscle may decrease fibrosis. In order to test 
this, members of our lab treated mice for 2 months, from 4 weeks of age to 12 weeks of 
age, and collected muscle tissue to test the pathological outcome in the mice. In order to 
see if the activation did alter fibrosis, Sarah Tuthill looked at fibrosis in diaphragm and 
quadriceps muscles using collagen I as a marker for fibrosis. She found that fibrosis was 
significantly reduced in the diaphragm, Figure 4. 
Figure 4. A. Diaphragm at 12 weeks of age in a control mdx mouse treated with vehicle solution 
alone stained for collagen I (green) and Dapi (blue). B. Diaphragm of an mdx mouse treated for 2 
months with Purmorphamine stained for collagen I and Dapi. C. Mdx mice treated for 2 months 
with purmorphamine show a significant decrease in collagen I deposition in the diaphragm. ** 
P<0.01. Control N=2, 
Treated N=3. Staining 
and quantifications done 
by Sarah Tuthill.  
When fibrotic tissue is 
deposited it replaces 
muscle tissue. It would 
be inferred that if you 
are decreasing fibrosis 
then less muscle tissue 
would be lost. This led 
us to see if the amount 
of tissue gained or lost 
was the outcome of 
activating Hh 
signalling. In order to test the amount of muscle tissue present, we looked at the number 
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of fibers within a specified area of tissue. We used tissues stained with laminin and 
counted the number of fibers per 
square millimetre of tissue, 
Figure 5.  
Figure 5.  In diaphragm of mice 
treated for 2 months quantified for 
the total number of fibers per mm². 
WT N=5, Control N= 6, Treated 
N=3. Staining and quantifications 
contributed by Samantha Devenport and Dr. Hong Wang.  
Although we saw no significant changes in muscle fibers per area in the diaphragm, there 
was a trend for an increased myofiber number in treated mice. We next asked if treatment 
improved regeneration. We quantified the percentage of myofibers with central nuclei, 
which denote a regenerated fiber, as a measure for regeneration in the tissue. We found 
that in the diaphragm of treated mdx mice there was a significant reduction in myofibers 
with central nuclei, denoting less fibers that have gone through regeneration, Figure 6. 
From this we could infer one of two things. Either, treatment is impairing regeneration, 
because there are less fibers being regenerated or, we are improving the structure of the 
muscle to the point where less fibers need to go through regeneration. To address this 
question we had to look at earlier time points to determine whether activation of Hh 
signalling by purmorphamine altered one or both key modulators of fibrosis: satellite cell 
function and inflammation. Therefore, in this thesis I am reporting the characterization of 
mdx mice at the end of a short pulse treatment with Purmorphamine from 8 to 9 weeks of 
age, before the 
onset of fibrosis.   
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Figure 6. A. Central Nuclei values compared to the total number of fibers in entire tissue 
sections of diaphragm and quadriceps in 2 month control and treated mice. ** P<0.01. 
Staining and quantifications contributed by Samantha Devenport and Dr. Hong Wang.   
Results 
Initial studies in the lab focused on the effects of long-term activation of Hh 
signaling from 4 to 12 weeks of age in mdx mice. These studies revealed a selective 
inhibition of fibrosis in the diaphragm. To better understand how the activation inhibited 
fibrosis, I performed short term, 1 week, treatments at 8 weeks of age, before the onset of 
fibrosis. We administered purmorphamine, a hedgehog agonist, IP twice a day in twelve 
hour intervals at a concentration for 100ul/10g body mass starting at 8 weeks of age. 
Control mice also received an injection of vehicle solution. After one week of treatment 
tissues were collected.  
General Inflammation          
  Since I was aiming to better understand the effects seen after two months of 
treatment in the mice, I first looked at inflammation as it contributes to fibrosis in mdx 
mice. To first look at inflammation I used a general marker for immune cells, CD45, a 
marker for Hematopoietic cells which includes all blood lineages, with the exception of 
red blood cells, to measure inflammation. The mice treated with purmorphamine were 
found to have a significant reduction in the inflammatory response in diaphragms 
compared to controls, however, the same results were not seen in the quadriceps, Figure 
7 A and B. Interestingly, the diaphragm of control mdx mice showed large areas of CD45 
staining while treated mice primarily showed small groups of CD45 positive cells 
interspersed between fibers. When comparing the inflammation to the general pathology 
of the tissue in controls versus treated mice there are stark differences. In areas where 
there is inflammation in control mice, the tissue has large patches of degeneration and 
regeneration seen throughout the tissue. These large areas of tissue remodeling are not 
seen in the treated mice. Rather, there are only small areas with some interstitial 
thickening and increased numbers of mononuclear cells, Figure 7 C and D. I carried out 
a similar analysis on mice treated for 2 months to determine whether this decrease in 
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inflammation was sustained. I found that here was a slight decrease in inflammation but 
nothing significant in the diaphragm, Figure 8.  
Figure 7.  A.CD45 (green) Immunostaining of diaphragm from 9 week old mdx mouse treated 
with purmorphamine from 8 to 9 weeks of age. B. Control mdx mouse, 9 weeks of age, CD45 
immunostaining. C.  Hematoxylin and Eosin sections of same tissue as A D. Hematoxylin and 
Eosin sections of same tissue as B. E. CD45 staining quantified at the total positive area 
measurement relative to total tissue area. Treatment with purmorphamine for Hh activation 
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significantly reduces general immune response in diaphragm tissue. F. The effects of Hh 
signaling activation is not seen in the quadriceps of the same mice. Control N=5, Treated N=6  * 
P<0.05 
Figure 8. Mice treated for 2 months with 
purmorphamine showed no difference in 
general inflammation by CD45 staining in the 
diaphragm.                                                                    
 
 
 
Satellite Cells  
Having previously seen an upward trend for the number of myofibers per area of 
tissue (Figure 5) we wanted to better understand the cause of this observation. The 
change could be due to decreased fibrosis or improved regeneration which is what led me 
to look at satellite cells. Satellite cells are known to be depleted in DMD and the mdx 
mouse. In order to determine if Hh signaling alters the amount of satellite cells in muscle, 
tissue sections were stained for Pax7, a marker of satellite cells, which was normalized to 
the total number of fibers in the tissue section for entire muscle, Figure 9. There was no 
difference between control and treated mice in the number of satellite cells in the 
diaphragm or the quadriceps. 
Figure 9. A. Pax7 (red) positive satellite cells overlapped with Dapi(blue) to show satellite cells 
(purple) in quadriceps tissue of 9 week old mice.  B. Pax7 positive cells shown in red in 
quadriceps tissue of 9 week old mice. C. No difference in diaphragm for Pax7 positive satellite 
cells after one week of Hh activation D. No difference in quadriceps for Pax7 positive cells after 
one week of Hh activation. Control N=5, Treated N=6 
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Satellite Cell Differentiation  
We next looked at whether Hh activation might improve satellite cell 
differentiation rather than activation. In order to quantify the effects that activated Hh 
signaling may have on regeneration, tissues were stained with eMHC, a marker of 
regenerating fibers and laminin, a marker of the basal lamina. On entire tissue sections, 
fibers were classified in three categories. The fiber could be labeled as “full regeneration” 
which means that the process was near completion and the entire basal lamina scaffold 
had been re-filled with a moyfiber; labeled as “normal regeneration”, where the fiber is 
still undergoing regeneration as evidenced by the presence of multiple small caliber 
myotubes inside the original basal lamina scaffold; and “branching” which denotes fibers 
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where myotubes have stopped growing prematurely and have started to deposit their own 
basal lamina thus generating branched fibers. These classifications can be seen in Figure 
10. 
 
Figure 10 A. Immunoflorescent staining for eMHC (green) to observe regeneration in treated 
mdx mice. Sections from mice treated with purmorphamine for 1 week from 8 weeks of age to 4 
weeks of age. Full regeneration shows fibers in which the satellite cells have fully fused and 
differentiated back to the original fiber size with no defects. Normal regeneration denotes a fiber 
that is actively regenerating. Nuclei (blue) can be seen in large quantities inside the cell and will 
continue to fuse and express eMHC or will be impaired and begin to branch. Branching fibers are 
those which have an impaired repair process and did no fuse properly. Rather, laminin (red) was 
deposited around fused areas and forms individual fibers that branch from each other rather than 
fusing into one larger fiber.  
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 In order to determine the extent of branching in the muscle I compared the different 
categories of regeneration between muscle.  The eMHC positive fibers were classified 
into the three groups of “full regeneration”, “normal regeneration” and “branching”. The 
total in each category was normalized to the total number of eMHC positive fibers in the 
tissue. Comparisons were made between quadriceps and diaphragms of 1 week treated 
mice, Figure 11.  
  
Figure 11. A. In mice treated for just one week, there was a significant amount of fibers that 
were able to regenerate fully with no impairments. B.  There is no difference in the number of 
fibers in the initial state of regeneration C. The number of fibers that become branched due to an 
impaired regeneration process is reduced. Note: For B-D the individual samples are denoted on 
the graphs rather than an average for the group to show distribution in each category. Control 
N=5, Treated N=6 *P<0.05   
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Fiber Damage  
With improved regeneration and a decrease in branched fibers it would be 
expected to see a decrease in damage in the muscle. Since the branched fibers are more 
prone to damage we wanted to see if decreasing their presence in muscle would decrease 
the damage. In order to measure this outcome I assessed damage sustained by the muscle 
using an IgG stain against mouse.  Fibers which show staining have been damaged and 
the number of damaged fibers relative to the total number of fibers was measured. Mice 
treated for two months showed a significant decrease in damage in the diaphragm but this 
improvement was not seen in the quadriceps. There was no decrease of damage in mice 
treated for one week in both muscle types, Figure 12. 
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Figure 12. A. Mice treated for two months 
with purmorphamine showed a significant 
decrease in IgG positive (necrotic) fibers, out 
of the total number of fibers in an entire tissue 
section in the diaphragm. B. In the same mice 
treated for 2 months there was no change seen 
in the quadriceps C. Diaphragm of mice 
treated for 1 week does not show a significant 
change in IgG positive fibers. D. The 
quadriceps of 1 week treated mice does not 
show a change in IgG positive fibers.  E. 
Image in Quadricep muscle of an IgG positive 
fiber to denote damage. The white arrow denotes a positive fiber. * P<0.05. For A and B, Control 
N=5, Treated N=3. For C and D Control N=4, Treated N=6. Staining of diaphragms from mice 
treated for 2 months completed by Sarah Tuthill.  
 
Discussion 
Current research is aimed at better understanding the mechanisms and pathways 
involved in DMD. With no cure available, finding a treatment that can alleviate the 
secondary effects of the loss of dystrophin is desired. Members of our lab discovered that 
myogenic differentiation of interstitial stem cells is dependent upon active Hedgehog 
signalling which is inhibited in the dystrophic muscle environment. It is important to 
define the broader role of this pathway in the progression of DMD.  
When aiming to better understand the Hh pathway it is important to look closely 
at the regeneration process as a whole in muscle.  
It is interesting to note the difference in the response to treatment between the quadriceps 
and the diaphragm muscles. There is consistently an effect seen in the diaphragm but not 
in the quadriceps compared to controls. The two muscles progress differently in the 
disease with the diaphragm being more severely affected. Because the quadriceps are not 
as severe there may be less room for improvement (Haslett et al., 2005). These contrasts 
may be due to different alterations in Hh signalling in each muscle.  Understanding this 
outcome is important to assess how the pathway affects muscle. In order to better 
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understand these contrasts, we are quantifying the decrease in Hh activity between 
diaphragm and quadriceps at different ages in mdx mice.  Testing a range of time points 
will potentially show an altered activation in the diaphragm compared to the quadriceps.  
In addition, Hh ligands could be identified in muscle sections to see if the quantity or 
location is different in diaphragm compared to quadriceps muscle. 
 Inflammation 
The inflammatory response plays a role in altering regeneration and fibrosis 
deposition so understanding how Hh signalling alters the inflammatory response is 
important. I found that inflammation was decrease in the diaphragms of mice treated for 
one week. However, a better understanding the characteristics of this decrease are 
important.  The presence of M1 and M2 macrophages can be studied as they are primary 
players in the immune response. Macrophages can be beneficial and promote 
regeneration, but in some cases they can be cytotoxic and can damage the muscle 
(Nguyen and Tidball, 2003), which is what can be seen in the mdx model. The decrease 
seen in the immune response after one week may be explained by a mechanism which 
controls this response and prevents negative effects from the macrophages. In order to 
test this hypothesis, cytokines involved in M1 and M2 macrophage activation can be 
tested at different time points in the repair process. It has been found that macrophages 
help to increase the proliferation of satellite cells but that they may prevent the 
differentiation of these cells (Merly et al., 1999; Tidball and Villalta, 2010) . In order to 
understand if there is an alteration in dystrophic muscle I am comparing the presence of 
macrophages in tissue. To assess the changes in M1 and M2 macrophages, a co-labeling 
is being done with F4/80 which is a marker of M1 macrophages and CD206, a marker for 
M2 macrophages. While the diaphragms have not yet been characterized, I have 
compared the differences in the quadriceps. Although there is not a significant difference 
in macrophage types, it is important to still look at the diaphragms as they continuously 
turn out differently than the quadriceps due to differences in disease progression. Our 
findings, along with those mentioned, may represent a connection between the decreased 
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inflammatory response seen and the improved regenerative properties of the treated 
muscle. 
Satellite Cells 
When we saw a decrease in fibrosis in mice treated for two months we wanted to 
better understand the cause of this reduction. Inflammation, along with alterations in the 
ability of satellite cells to differentiate can affect fibrosis. Using the Pax7 staining to 
show satellite cells there was no difference seen between treated mice and control mice. 
Although there is no effect seen, this assay does not distinguish between those that go 
through differentiation successfully. Therefore, although the presence of satellite cells is 
the same, those in the mdx mouse may not be able to differentiate as successfully which 
leads to branched fibers. Or, there could be no differentiation at all due to an impaired 
process. It would be important to further study the fate of the activated cells to better 
understand the specific processes that are occurring.   
If regeneration is improved and there are less branched fibers, which are more 
easily damaged, it would be expected that there is less damage in the muscle. In order to 
see if this assumption was correct, I conducted an IgG stain to denote necrotic fibers. 
There was no significant difference between treated and control mice after just one week 
of treatment. What may be suggested here is due to the early stage in the disease, treated 
mice have not had a chance to catch up on preventing damage compared to controls. New 
fibers are beginning to regenerate in both tissues so there may not have been enough time 
between regeneration and tissue collection for a significant number of fibers to become 
damaged.  In order to see if this assumption was correct and that the treatments were 
preventing damage I looked at an IgG staining in the mice treated for 2 months. The 
diaphragms, which were stained by Sarah Tuthill, showed a significant reduction in 
damage. The quadriceps however, did not see the same changes.  The reduction in the 
diaphragm may be due to the decrease of branching in the muscle which lessens 
contractile damage. Although the Hh signalling activation does not eliminate the damage, 
the decrease can reduce inflammation and further need for extensive regeneration. This 
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outcome would lead to a decrease in the deposition of fat and fibrosis and improve the 
muscle environment.   
Fibrosis 
If the muscle is damaged and is not able to properly repair, fibrotic tissue is 
deposited. Fibrosis within muscle can impair function and can decrease the amount of 
muscle fibers present in a tissue. When regeneration fails, cells can begin to release pro-
fibrotic signals and cause the deposition of fibrosis. While this is normal in muscle as 
aging occurs it is exaggerated in DMD. It would be expected that since the inflammation 
is more controlled and regeneration is improving that there would be less fibrosis 
deposition which is what we see in the diaphragm. My findings support the notion that 
the treatment is not impairing regeneration, as suggested by less centrally nucleated fibers 
after long term treatment. Rather, there is less damage, improved myofiber regeneration, 
and less deposition of fibrotic tissue.  
Long Term Outcome 
Since we have seen alterations in inflammation, regeneration, damage and fibrosis 
in short and long term treatments we wanted to see the effect on functional ability in the 
mice. In order to measure changes, Dr. Christopher Penton conducted an exercise 
induced fatigue test which monitors their movement pre and post exercise. . We found 
that just after one month of treatment, mice had a significant reduction in fatigue 
compared to controls. This result was carried out after two months of treatment, Figure 
13.  
Figure 13. A behavioural test to 
observe resistance to fatigue was 
done by Dr. Christopher Penton in 
mice treated for two months with 
Purmorphamine. Mice were 
monitored in an open field activity 
cage for 1 hour pre and post 
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exercise. Mice were run for 10 minutes at 10m/min on a 15 degree decline. This figure shows 
decrease in rearing in mice after exercise. The black line denotes the decrease seen in WT mice. 
**P<0.01 
While utilizing purmorphamine as an Hh agonist improves pathology, using a 
genetic model to study the effects is also of interest. In order to observe if the same 
changes would be present we are working on characterizing the same aspects in a genetic 
model known as the patched-1 mouse. We have back crossed some of the mice to the 5cv 
and WT genotypes and are seeing if the model can reproduce the same results with 
activation throughout life. The patched mouse does not actually activate hedgehog 
signaling, rather it eliminates a copy of patched and therefore allows smoothened to be 
activated more readily even at lower concentrations of ligand. If similar results are seen 
through a genetic model, this research could potentially be applied via gene therapy.  
All of the effects that lead to the pathology in DMD have yet to be understood. 
The Hh pathway is not commonly studied or well understood in muscle, and dystrophic 
muscle in particular. This study has shown that the pathway can positively alter 
pathology so it is of importance to characterize the effects. While it is beyond the scope 
of this thesis it is important to better understand the mechanisms involved in the pathway. 
If Hh signaling only alters one of the areas affected but it has a cascading effect to other 
secondary effects it would be important to understand the way this occurs. More 
knowledge on the pathway functions can help in better understanding DMD along with 
providing the opportunity to study potential therapeutic treatments.   
Abbreviations 
Duchenne Muscular Dystrophy: DMD  
Hedgehog: Hh 
Extra Cellular Matrix: ECM 
Dystrophin Glycoprotein Complex: DGC  
Intraperitoneal: IP  
   
31 
 
Wild Type: WT  
Smoothened: Smo  
Patched-1: Ptch 
Transforming growth factor beta: TGF-β 
Paired Box 7: Pax7 
Inducible Nitric Oxide Synthase: iNOS  
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